Study of Stereotactic Radiotherapy for Breast Cancer

  • End date
    Aug 1, 2024
  • participants needed
  • sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Updated on 28 January 2021
sentinel node
breast-conserving surgery
ductal carcinoma
sentinel lymph node biopsy


This is a Phase II trial of preoperative stereotactic radiation to the breast for low risk breast cancer.


This is a single arm phase II study design, evaluating the pathologic response (primary endpoint) as well as toxicity, cosmetic outcome, quality of life, and translational correlates (secondary endpoints) to pre-operative stereotactic body radiotherapy (SBRT) to intact breast tumors in patients with hormone-receptor positive early stage breast cancer.

Condition Breast Cancer, Breast Cancer Diagnosis, breast carcinoma, cancer, breast
Treatment Stereotactic Body Radiation SBRT
Clinical Study IdentifierNCT03043794
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last Modified on28 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 50 yrs?
Are you female?
Do you have Breast Cancer?
Do you have any of these conditions: breast carcinoma or Breast Cancer or cancer, breast or Breast Cancer Diagnosis?
Do you have any of these conditions: breast carcinoma or cancer, breast or Breast Cancer Diagnosis or Breast Cancer?
Do you have any of these conditions: Breast Cancer Diagnosis or cancer, breast or Breast Cancer or breast carcinoma?
Female sex
Age > or = to 50 years of age
Invasive ductal carcinoma
Clinically and radiographically T1 tumor
Clinically node negative
Clearly demarcated tumor on magnetic resonance imaging (MRI), as determined by treating physician (MRI may be done after enrollment if not done prior)
Planning breast conserving surgery including sentinel node biopsy
% expression of ER and/or PR
HER2- using the current College of American Pathologists guidelines
Willing and able to provide informed consent

Exclusion Criteria

Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma
Pure DCIS without invasive cancer
Patients who have received or will be receiving neoadjuvant systemic therapy, endocrine therapy, or targeted agents
Breast implant in the involved breast unless the implant will be removed prior to initiation of study treatment
Positive pregnancy test
Subjects without placement of a biopsy clip at the diagnostic procedure who are unwilling to undergo clip placement
Unable to meet dosimetric constraints due to tumor location and/or patient anatomy
Planning mastectomy
Unable to tolerate prone positioning
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note